| Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. | |
| | |
MedLine Citation:
|
PMID: 9597523 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cost-effectiveness analyses are routinely performed to determine whether the additional cost of a novel therapy is balanced by additional effectiveness. The definitions of costs and effects involve a variety of assumptions, both in general economic terms and with regard to the specific medical setting under consideration. Similarly, differing criteria for acceptability of cost-effectiveness estimates can be used to generate different conclusions regarding cost-effectiveness. The issues and problems inherent in economic evaluation are discussed by an analysis of findings with the platelet glycoprotein IIb/IIIa inhibitor abciximab in the EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) study in high-risk patients undergoing percutaneous transluminal coronary angioplasty. |
| | |
Authors:
|
B A van Hout; L Bowman; D J Zelinger; M L Simoons |
Related Documents
:
|
9141373 - Causes of failed angioplasty for acute myocardial infarction assessed by intravascular ... 8227783 - Percutaneous transluminal coronary angioplasty of one major coronary artery when the co... 1848003 - Neonatal adaptation: cardiac adrenergic effector mechanisms after birth in newborn sheep. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: European heart journal Volume: 19 Suppl D ISSN: 0195-668X ISO Abbreviation: Eur. Heart J. Publication Date: 1998 Apr |
Date Detail:
|
Created Date: 1998-07-16 Completed Date: 1998-07-16 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8006263 Medline TA: Eur Heart J Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: D59-66 Citation Subset: IM |
Affiliation:
|
Erasmus University Rotterdam, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angioplasty, Transluminal, Percutaneous Coronary*
/
economics Antibodies, Monoclonal / economics, therapeutic use* Coronary Disease / drug therapy, economics, therapy* Cost-Benefit Analysis Humans Immunoglobulin Fab Fragments / economics, therapeutic use* Platelet Aggregation Inhibitors / economics, therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Randomized Controlled Trials as Topic Treatment Outcome United States |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 143653-53-6/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Abciximab therapy in percutaneous intervention: economic issues in the United States.
Next Document: Tracking the contribution of a family medicine clerkship to the clinical curriculum.